| Indicator | Current Period | Prior-Year Period | YoY |
|---|---|---|---|
| Revenue | ¥457.9B | ¥474.4B | -3.5% |
| Operating Income | ¥7.5B | ¥14.3B | -47.6% |
| Pre-tax Profit | ¥7.5B | ¥5.9B | +26.8% |
| Net Income | ¥4.5B | ¥1.0B | +331.4% |
| ROE | 0.4% | 0.1% | - |
FY2026 Q1 results: Revenue ¥457.9B (vs prior year -¥16.5B, -3.5%), Operating Income ¥7.5B (vs prior year -¥6.8B, -47.6%), Ordinary Income ¥7.5B (vs prior year +¥1.6B, +26.9%), Net Income attributable to owners of the parent ¥4.2B (vs prior year +¥4.1B, +3314.2%). Despite some revenue-growing segments, the consolidated result was lower revenue and lower profit overall; operating margin deteriorated to 1.6% from 3.0% a year earlier (-1.4pt). Conversely, net income rose substantially year-on-year despite the large drop in operating income, reflecting a reversal from the prior year’s low profit base.
[Revenue] Revenue ¥457.9B (YoY -3.5%) declined primarily due to weakening demand in the Devices Business. By segment, Industrial Materials ¥195.3B (+4.0%), Medical ¥141.3B (+3.7%), and Others ¥17.3B (+17.2%) recorded revenue growth, while Devices ¥104.0B (-23.3%) dragged on the overall figure. Industrial Materials benefited from steady demand for decorative films and molded products; Medical benefited from increased orders for medical device CDMO. Devices saw double-digit revenue declines due to weak demand for film touch sensors for smartphones and similar products.
[Profitability] Gross profit ¥110.5B (gross margin 24.1%) was down ¥5.2B YoY, with gross margin down 1.3pt from 25.4% a year earlier. Selling, general and administrative expenses were ¥100.2B (SG&A ratio 21.9%), up ¥2.7B YoY, resulting in Operating Income ¥7.5B (operating margin 1.6%), a substantial YoY decline of 47.6%. By segment, Industrial Materials Operating Income ¥7.1B (-30.0%) saw margin compressed to 3.6% due to higher raw material and energy costs; Devices ¥3.9B (-54.7%) saw margin compressed to 3.8% due to weaker demand and price competition; Medical ¥8.4B (+13.3%) secured margin of 6.0% through improved utilization. Corporate-level adjustments of -¥12.9B pressured consolidated operating income. Financial income ¥4.6B and financial expenses ¥4.6B nearly offset, leaving Ordinary Income at ¥7.5B, similar to operating income. After pre-tax profit ¥7.5B and corporate taxes ¥3.0B (effective tax rate 40.3%), Net Income attributable to owners of the parent was ¥4.2B. In conclusion, while Medical’s revenue and profit growth contributed positively, substantial declines in Devices and margin deterioration in Industrial Materials led to overall lower revenue and profit.
Industrial Materials achieved revenue ¥195.3B (+4.0%) but Operating Income ¥7.1B (-30.0%) and margin 3.6%, reflecting significant margin deterioration. Higher raw material and energy costs and new product launch expenses pressured profits. Devices recorded revenue ¥104.0B (-23.3%), Operating Income ¥3.9B (-54.7%), and margin 3.8%, showing pronounced revenue and profit declines due to weak demand for film touch sensors for smartphones and price competition. Medical was the only segment with revenue and profit growth: Revenue ¥141.3B (+3.7%), Operating Income ¥8.4B (+13.3%), margin 6.0%, driven by higher CDMO utilization for medical devices. Others posted Revenue ¥17.3B (+17.2%), Operating Income ¥1.0B (+157.9%), and margin 5.7%, with the information & communication business performing well.
[Profitability] Operating margin 1.6% (prior year 3.0%) deteriorated by 1.4pt; net margin 0.9% (prior year 0.0%) improved by 0.9pt. ROE 0.4% remained in a flat range YoY, with declining operating margin weighing on profitability. Gross margin 24.1% declined 1.3pt from 25.4% a year earlier, impacted by Devices price competition and Industrial Materials cost increases. [Cash Quality] Operating Cash Flow (OCF) ¥39.7B is approximately 9.4x Net Income ¥4.2B, indicating very high cash quality, with AR collection improvement +¥31.5B contributing while inventory increase -¥33.2B absorbed cash. OCF subtotal (before working capital changes) was ¥46.9B versus working capital change -¥7.2B, indicating good cash conversion efficiency. [Investment Efficiency] Total asset turnover 0.18x (annualized 0.73x) remained low due to inventory increase to ¥355.0B and lower sales. Capex ¥13.8B (3.0% of sales) was approximately 54% of depreciation ¥25.6B, indicating restrained investment and not an aggressive capex phase. [Financial Soundness] Equity Ratio 46.5% (prior year 46.1%) was flat; current ratio 152%; Cash and Cash Equivalents ¥387.2B indicates strong liquidity. Interest-bearing debt ¥614.7B (current ¥326.1B, non-current ¥288.6B); net debt after deducting cash ¥387.2B is approximately ¥227B, within acceptable range, but EBIT ¥7.5B versus financial expenses ¥4.6B yields interest coverage of about 1.6x, leaving room for improvement in earnings resilience.
OCF ¥39.7B (prior year -¥10.9B) improved by ¥506.4B, a significant improvement and about 9.4x Net Income ¥4.2B, indicating very high quality. Working capital movements included AR collection improvement +¥31.5B and AP increase +¥5.5B that supported cash, while inventory increase -¥33.2B absorbed cash, leaving inventory pressure. Investing cash flow -¥15.6B was mainly capex -¥13.8B; capital expenditures were restrained at 3.0% of sales. Proceeds from sale of investment securities ¥1.0B provided cash inflow. Financing cash flow -¥35.4B mainly comprised repayment of short-term borrowings -¥64.9B, bond issuance proceeds +¥54.7B, and dividend payments -¥11.8B, reflecting a lengthening of funding structure. Free Cash Flow ¥24.1B (OCF ¥39.7B - Investing CF ¥15.6B) remained positive, preserving liquidity after dividend payments. Foreign exchange translation effect +¥6.4B lifted Cash and Cash Equivalents to ¥387.2B (YoY +¥11.8B), maintaining a robust liquidity cushion. OCF/EBITDA (approximate EBITDA ¥33.1B = EBIT ¥7.5B + D&A ¥25.6B) is about 1.2x, showing good cash conversion efficiency; OCF subtotal ¥46.9B less working capital change -¥7.2B, tax payments -¥5.0B, and net interest paid -¥3.6B generated the reported OCF.
This period’s results are driven mainly by recurring operations; one-off items were limited. Financial income ¥4.6B and financial expenses ¥4.6B nearly offset, so non-operating items did not materially lift profits. Other income ¥2.2B and other expenses ¥4.0B were each below 1% of sales and immaterial, implying the need for operating-led improvements. OCF substantially exceeded Net Income (~9.4x) and the accrual ratio was -1.4%, indicating cash-driven, high-quality earnings. However, the gap between Ordinary Income ¥7.5B and Net Income ¥4.2B stems from high tax burden (effective tax rate 40.3%); if the effective tax rate remains structurally high, it will constrain net income growth. Equity in earnings of affiliates -¥1.0B was a minor burden. Comprehensive income ¥22.6B (attributable to owners of the parent ¥22.0B) significantly exceeded net income, driven by foreign currency translation differences +¥13.3B and other comprehensive income +¥4.4B, which include temporary valuation gains.
Full Year (FY) forecast: Revenue ¥1,980.0B (YoY +1.6%), Operating Income ¥70.0B (YoY +73.3%), Net Income attributable to owners of the parent ¥32.0B (YoY +219.4%), EPS ¥67.49, Dividend ¥25.00. Q1 progress versus full-year forecast: Revenue 23.1% (standard progress 25%: -1.9pt), Operating Income 10.7% (standard -14.3pt), Net Income 13.2% (standard -11.8pt), showing notable lag in profit progress. Background factors include weak Devices demand and inventory adjustments, margin deterioration in Industrial Materials, and concentration of corporate expenses in H1. Achieving the full-year target assumes H2-weighted plan execution (price revisions and mix improvement, higher Medical utilization, cost control, inventory reduction) and improvement in operating leverage in H2. Note that the earnings forecast was revised during this quarter to improve planning accuracy.
Dividend payments in Q1 were ¥11.8B, sufficiently covered by Free Cash Flow ¥24.1B. Full-year forecast dividend ¥25.00 (prior year ¥25.00) is unchanged; the annual dividend total of approximately ¥11.8B against forecast Net Income attributable to owners of the parent ¥32.0B implies a payout ratio of about 37%, a sustainable level. No share buybacks were executed this period (prior year -¥6.6B), indicating a dividend-centric balanced capital allocation. Net debt of approximately ¥227B versus cash ¥387.2B provides a substantial cushion, preserving flexibility to continue dividends.
Demand volatility in the Devices business: Demand for film touch sensors for smartphones and related products fell sharply YoY (-23.3%), and Operating Income plunged -54.7%. The consumer electronics market is highly cyclical; prolonged inventory adjustments or price competition could sustain weak profitability.
Margin deterioration in Industrial Materials: Although revenue increased +4.0%, Operating Income declined -30.0% and margin fell to 3.6%. Rising raw material and energy costs and new product launch expenses are pressuring profits; delays in passing on costs or continued cost increases could further compress gross margins.
Inventory stagnation and working capital pressure: Inventory ¥355.0B rose ¥36.1B YoY and absorbed ¥33.2B of cash from OCF. Days Inventory Outstanding (DIO) is estimated at 373 days and has lengthened; delayed demand recovery or slow inventory reduction could tie up working capital and pressure cash conversion.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 1.6% | 6.8% (2.9%–9.0%) | -5.2pt |
| Net Margin | 1.0% | 5.9% (3.3%–7.7%) | -4.9pt |
Profitability is well below the industry median, with both operating margin and net margin at lower-tier levels.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth (YoY) | -3.5% | 13.2% (2.5%–28.5%) | -16.7pt |
Revenue growth lags the industry median 13.2% by a wide margin (-3.5%), impacted by weak Devices demand.
※ Source: Company compilation
Strong cash generation and solid financial base, but a profitability gap: OCF ¥39.7B and Free Cash Flow ¥24.1B demonstrate high cash generation; Equity Ratio 46.5% and Cash ¥387.2B indicate a robust financial base. However, Operating Margin 1.6% is well below the industry median 6.8%, and full-year progress for operating income at 10.7% is well behind the standard 25%. Execution of H2 measures—price revisions, mix improvement, inventory reduction, and cost control—will be key to achieving the full-year targets.
Medical-led growth and qualitative improvement toward less cyclical businesses: Medical is the only segment with revenue +3.7%, Operating Income +13.3%, and margin 6.0%, aided by higher CDMO utilization. Increasing the share of less cyclical Medical could improve portfolio quality over the medium term. However, given Devices’ demand volatility and goodwill ¥339.3B (28.6% of net assets), continued monitoring for impairment risk is required.
This report was automatically generated by AI analyzing XBRL earnings release data. It is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by our company based on public financial statements. Investment decisions are your responsibility; consult a professional advisor as needed.